Novo Nordisk A/S buy heckma01
Summary
This prediction ended on 29.03.17 with a price of €31.69. With a performance of -3.83%, the BUY prediction for Novo Nordisk A/S by heckma01 closed slightly in the red. heckma01 has 50% into this predictionNovo Nordisk is a Danish pharmaceutical company that specializes in diabetes care and research. It is considered to be one of the largest companies in the world that focus exclusively on diabetes management, with a product portfolio that ranges from insulin treatment to obesity management. The company is listed on the Copenhagen Stock Exchange and has gained global recognition for its commitment to sustainable business practices and its contribution to diabetes research and treatment. Novo Nordisk has a strong financial track record and has consistently delivered solid returns to investors over the years.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Novo Nordisk A/S | - | - | - | - |
iShares Core DAX® | -3.429% | 5.085% | 15.455% | 12.600% |
iShares Nasdaq 100 | -6.121% | 0.593% | 16.379% | 27.048% |
iShares Nikkei 225® | -7.364% | 5.479% | 6.970% | -3.061% |
iShares S&P 500 | -4.366% | 2.019% | 18.650% | 32.317% |
Comments by heckma01 for this prediction
In the thread Novo Nordisk A/S diskutieren
heckma01 stimmt dem Sentiment von 'Buy' zu
heckma01 stimmt am 29.01.2017 dem Buy-Gesamtsentiment mit dem Kursziel 39.94€ zu.